摘要
补体受体1(CR1)(CD35; C3B / C4B受体)是许多血液细胞的跨膜蛋白。一旦切割,可溶性补体受体1型(SCR1)将相反的效果作为强大的补充抑制剂。本研究解决了SCR1是否在正规和各种炎症疾病患者的支气管肺泡灌洗(BAL)中发现了SCR1的问题。在这种回顾性研究中,通过酶联免疫吸附测定技术分析了124例急性和慢性炎症肺病理学患者的标本和临床资料,通过酶联免疫吸附测定技术进行SCR1的分析。在获得的SCR1水平和BAL的成分之间进行相关性。培养人肺泡巨噬细胞以确定其SCR1的分泌能力。显示来自正常受试者的肺泡巨噬细胞释放体外Sc1。此外,Scr1存在于正常对照组中,急性炎症性肺病(如急性呼吸窘迫综合征(ARDS),细菌和肺细胞患者,细菌和肺炎,以及间质肺纤维化和结节病等慢性炎症疾病中显着增加。在ARDS,细菌和P. Carinii肺炎的BAL中,SCR1与绝对中性粒细胞计数之间存在良好的相关性。在结节病,发现了Bal淋巴细胞计数的相关性。 Serum sCR1 was not increased in patients compared to controls. Soluble complement receptor type 1 (sCR1) is found in the bronchoalveolar lavage in health as well as in acute and chronic inflammatory disease. Alveolar macrophages are capable of releasing sCR1 in vitro and may be the main physiological source of sCR1 in the alveoli. The good correlation between sCR1 and the absolute neutrophil or lymphocyte numbers in bronchoalveolar lavage of inflammatory diseases suggests a predominant role of leucocytes for the release of sCR1 in such conditions. The release of this inhibitor of complement may be crucial to control and reduce complement activation and thus prevent lung injury.